CLIMB BIO INC

CLYMNASDAQ

🏆 #2137 by market capEarnings Nov 5US Equity

$395.09▲ $7.98 (+2.02%)

Simulated price

1h—

24h▲ 2.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$778M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for CLYM.

Trading Snapshot

Day Range: $390.69 – $401.62
52-Week Range: $1.54 – $14.53
Volume: $3.61B
Avg Volume: $2.89B
Shares Outstanding: 57.3M
Next Earnings: Sep 30, 2026

Fundamentals Snapshot

Annual Revenue: $62M
Last Q Revenue: $16M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.78
Dividend Yield: —

Why Investors Own CLYM

✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
✓Healthy economics — 48% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$62M▲ +55.1% YoY

Gross Margin (TTM)

48.1%▲ +3.5% YoY

Operating Income (TTM)

$22M▲ +55.1% YoY

Free Cash Flow (TTM)

$13M▲ +55.1% YoY

About CLIMB BIO INC

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

🦦